In order to continuously implement new products and services for his customers, Oncomedics is involved in 2 R&D projects with external partners.
BioCapteur – CCREMS:
Oncomedics is one of the six SMEs involved in the IMODI research project. IMODI has been designed to ensure the selection of new effective treatments to combat cancer (Prostate, Lung, Liver, Breast, Ovary, Pancreas, Lymphoma, AML and Myeloma. The aim of this initiative is to pool the resources allocated to the development, profiling and evaluation of more than 200 predictive experimental cancer models and a wide range of derivative biological products and tests for molecular selection. The project also plans to create a centralized biobank with more than 40,000 biological samples and powerful data analysis tools designed to identify tumor and immunological biomarkers, as well as those coming from the microbiome.
Under the management and coordination of Oncodesign, the 7 year project brings together 6 international pharmaceutical groups (Sanofi, Servier, Ipsen, Pierre Fabre), 6 SMEs (Oncomedics, Ariana Pharma, CTI BIOTECH, Oncodesign, Modulbio, Biofortis) and 7 French institutions (Inserm, CNRS, the Georges Francois Leclerc Center in Dijon, the Leon Berard Center in Lyon for cancer research and treatment, Synergie Lyon Cancer, the University of Strasbourg and Toulouse University Hospital). Each organization belongs to one of 5 competitiveness clusters with authority to certify projects: Medicen, for the Paris Region, Alsace Biovalley, Lyonbiopole, Atlanpole Biotherapies in Nantes and Cancer-Bio-Sante in Toulouse.
IMODI will benefit from EUR 13.4 million of public funding after the final signing with OSEO. These subsidies and reimbursable advances will be allocated between the project’s French institutions and financed partner SMEs.
In this initiative, the unique experience of Oncomedics has been recognized to prepare primary cancer cell cultures from cancer patients with particularly high medical needs. In exchange to its role, Oncomedics will benefit of the cross-fertilization with the other partners and will have access to patient derived xenografts models which are considered to represent the heterogeneity of human cancers and advanced preclinical models. Oncomedics will extensively develop and characterize these new collections of patient-derived cancer models to propose new assays for its customers. IMODI is the extension of the previous initiative CREMEC described in the following reference: Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer.Julien S, Merino-Trigo A, Lacroix L, Pocard M, Goéré D, Mariani P, Landron S, Bigot L, Nemati F, Dartigues P, Weiswald LB, Lantuas D, Morgand L, Pham E, Gonin P, Dangles-Marie V, Job B, Dessen P, Bruno A, Pierré A, De Thé H, Soliman H, Nunes M, Lardier G, Calvet L, Demers B, Prévost G, Vrignaud P, Roman-Roman S, Duchamp O, Berthet C.Clin Cancer Res. 2012 Oct 1;18(19):5314-28.